Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer
© 2023 Wiley-VCH GmbH..
Pyroptosis, an emerging mechanism of programmed cell death, holds great potential to trigger a robust antitumor immune response. Platinum-based chemotherapeutic agents can induce pyroptosis via caspase-3 activation. However, these agents also enhance cyclooxygenase-2 (COX-2) expression in tumor tissues, leading to drug resistance and immune evasion in pancreatic cancer and significantly limiting the effectiveness of chemotherapy-induced pyroptosis. Here, an amphiphilic polymer (denoted as PHDT-Pt-In) containing both indomethacin (In, a COX-2 inhibitor) and platinum(IV) prodrug (Pt(IV)) is developed, which is responsive to glutathione (GSH). This polymer self-assemble into nanoparticles (denoted as Pt-In NP) that can disintegrate in cancer cells due to the GSH responsiveness, releasing In to inhibit the COX-2 expression, hence overcoming the chemoresistance and amplifying cisplatin-induced pyroptosis. In a pancreatic cancer mouse model, Pt-In NP significantly inhibit tumor growth and elicit both innate and adaptive immune responses. Moreover, when combined with anti-programmed death ligand (α-PD-L1) treatment, Pt-In NP demonstrate the ability to completely suppress metastatic tumors, transforming "cold tumors" into "hot tumors". Overall, the sustained release of Pt(IV) and In from Pt-In NP amplifies platinum-drug-induced pyroptosis to elicit long-term immune responses, hence presenting a generalizable strategy for pancreatic cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
---|---|
Enthalten in: |
Advanced materials (Deerfield Beach, Fla.) - 36(2024), 11 vom: 13. März, Seite e2310456 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yu, Bingzheng [VerfasserIn] |
---|
Links: |
---|
Themen: |
49DFR088MY |
---|
Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/adma.202310456 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365827118 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM365827118 | ||
003 | DE-627 | ||
005 | 20240315232943.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/adma.202310456 |2 doi | |
028 | 5 | 2 | |a pubmed24n1330.xml |
035 | |a (DE-627)NLM365827118 | ||
035 | |a (NLM)38092007 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yu, Bingzheng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.03.2024 | ||
500 | |a Date Revised 15.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 Wiley-VCH GmbH. | ||
520 | |a Pyroptosis, an emerging mechanism of programmed cell death, holds great potential to trigger a robust antitumor immune response. Platinum-based chemotherapeutic agents can induce pyroptosis via caspase-3 activation. However, these agents also enhance cyclooxygenase-2 (COX-2) expression in tumor tissues, leading to drug resistance and immune evasion in pancreatic cancer and significantly limiting the effectiveness of chemotherapy-induced pyroptosis. Here, an amphiphilic polymer (denoted as PHDT-Pt-In) containing both indomethacin (In, a COX-2 inhibitor) and platinum(IV) prodrug (Pt(IV)) is developed, which is responsive to glutathione (GSH). This polymer self-assemble into nanoparticles (denoted as Pt-In NP) that can disintegrate in cancer cells due to the GSH responsiveness, releasing In to inhibit the COX-2 expression, hence overcoming the chemoresistance and amplifying cisplatin-induced pyroptosis. In a pancreatic cancer mouse model, Pt-In NP significantly inhibit tumor growth and elicit both innate and adaptive immune responses. Moreover, when combined with anti-programmed death ligand (α-PD-L1) treatment, Pt-In NP demonstrate the ability to completely suppress metastatic tumors, transforming "cold tumors" into "hot tumors". Overall, the sustained release of Pt(IV) and In from Pt-In NP amplifies platinum-drug-induced pyroptosis to elicit long-term immune responses, hence presenting a generalizable strategy for pancreatic cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a chemotherapy | |
650 | 4 | |a cyclooxygenase 2 | |
650 | 4 | |a immunotherapy | |
650 | 4 | |a platinum drug | |
650 | 4 | |a pyroptosis | |
650 | 7 | |a Prodrugs |2 NLM | |
650 | 7 | |a Platinum |2 NLM | |
650 | 7 | |a 49DFR088MY |2 NLM | |
650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
650 | 7 | |a EC 1.14.99.1 |2 NLM | |
650 | 7 | |a Cisplatin |2 NLM | |
650 | 7 | |a Q20Q21Q62J |2 NLM | |
650 | 7 | |a Polymers |2 NLM | |
700 | 1 | |a Wang, Yushu |e verfasserin |4 aut | |
700 | 1 | |a Bing, Tiejun |e verfasserin |4 aut | |
700 | 1 | |a Tang, Yujing |e verfasserin |4 aut | |
700 | 1 | |a Huang, Jia |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Haihua |e verfasserin |4 aut | |
700 | 1 | |a Liu, Chaoyong |e verfasserin |4 aut | |
700 | 1 | |a Yu, Yingjie |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advanced materials (Deerfield Beach, Fla.) |d 1998 |g 36(2024), 11 vom: 13. März, Seite e2310456 |w (DE-627)NLM098206397 |x 1521-4095 |7 nnns |
773 | 1 | 8 | |g volume:36 |g year:2024 |g number:11 |g day:13 |g month:03 |g pages:e2310456 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/adma.202310456 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 36 |j 2024 |e 11 |b 13 |c 03 |h e2310456 |